ROUNDTABLE

INTERVIEW

Guy Furness

Kymanox

Interview: Kymanox Executive Advisors Mathias Romacker, Fran DeGrazio & Paul Jansen

Mathias Romacker, Fran DeGrazio and Paul Jansen sit down with Guy Furness, to discuss what it is that has driven Kymanox’s rapid rise in the drug delivery space and what makes the consulting company’s model so successful, as well as to share their expertise on a variety of topics in an illuminating discussion, including connectivity, how large and small drug developers engage with consultancies, 5 mL autoinjectors and the interface between drug primary packaging and delivery devices.

ROUNDTABLE

Michael Morgan

Lonza

ROUNDTABLE: TRENDS AND INNOVATIONS IN ORAL DRUG DELIVERY

Michael Morgen of Lonza Bend, Torkel Gren of Recipharm, and Yogesh Sadhale of Metrics Contract Services, discuss the current trends and innovations influencing oral drug delivery development and what their respective companies can offer to pharma in this space.

ROUNDTABLE

Frédérique Bordes-Picard

Lonza

ROUNDTABLE: CAPSULE-BASED DRY POWDER INHALERS

Frédérique Bordes-Picard of Lonza, Marco Franza of Berry, Mirjam Kobler of Meggle, and Marco Laackmann of Harro Höfliger, discuss the accelerating development potential of capsule-based dry powder inhalers (DPIs) and the potential of these effective and efficient drug delivery devices in the modern drug delivery market.

ROUNDTABLE

Sebastian Gerner

Alliance to Zero

ROUNDTABLE: ALLIANCE TO ZERO

Sebastian Gerner, Robert O’Beirn and Sabrina Gérard talk with ONdrugDelivery about the Alliance to Zero, an association for pharma and biotech supply chain companies that aims to facilitate the transition of the pharma sector to compliance with net-zero emissions.

ROUNDTABLE

Dr Jeremy Drummond

ROUNDTABLE: JEREMY DRUMMOND, MEDPHARM; STEPHEN RODE, LONZA; AND TORKEL GREN, RECIPHARM

In this roundtable discussion, Jeremy Drummond, Stephen Rode and Torkel Gren discuss trends with different drug dosage forms for different routes of administration, the rise of patient centricity including the shift from the blockbuster model to more tailored products.